Home > Boards > US Listed > Biotechs > Mind Medicine (MindMed) Inc (MNMD)

18-MC Trial - Connecting the Dots to J&J

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
PyroStocks Member Profile
 
Followed By 57
Posts 2,803
Boards Moderated 2
Alias Born 08/21/15
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/7/2021 4:20:40 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/2/2021 8:46:50 AM
MindMed to Participate at the Benzinga Global Small Cap Conference PR Newswire (US) - 12/2/2021 7:30:00 AM
MindMed to Participate at the Benzinga Global Small Cap Conference PR Newswire (Canada) - 12/2/2021 7:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/1/2021 8:47:01 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/30/2021 8:27:07 AM
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin PR Newswire (Canada) - 11/30/2021 7:30:00 AM
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin PR Newswire (US) - 11/30/2021 7:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2021 8:32:31 AM
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures PR Newswire (US) - 11/16/2021 7:30:00 AM
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures PR Newswire (Canada) - 11/16/2021 7:30:00 AM
Mind Medicine reports Q3 results Seeking Alpha - 11/15/2021 8:11:09 AM
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline PR Newswire (Canada) - 11/15/2021 7:30:00 AM
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline PR Newswire (US) - 11/15/2021 7:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2021 7:57:36 AM
MindMed to Present at the Jefferies London Healthcare Conference PR Newswire (Canada) - 11/12/2021 7:30:00 AM
MindMed to Present at the Jefferies London Healthcare Conference PR Newswire (US) - 11/12/2021 7:30:00 AM
COMPASS Pathways drops 21% on psilocybin therapy results; drags down MindMed Seeking Alpha - 11/9/2021 10:14:07 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/5/2021 12:27:07 PM
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board PR Newswire (US) - 11/5/2021 7:30:00 AM
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board PR Newswire (Canada) - 11/5/2021 7:30:00 AM
Psychedelics Offer Hope for Mental Disorders, Addiction NetworkNewsWire - 11/3/2021 8:45:00 AM
MindMed to Present at Web Summit on Future of Mental Health PR Newswire (US) - 11/1/2021 7:30:00 AM
MindMed to Present at Web Summit on Future of Mental Health PR Newswire (Canada) - 11/1/2021 7:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/26/2021 12:53:03 PM
PyroStocks   Monday, 04/26/21 02:40:54 PM
Re: None
Post # of 7313 
18-MC Trial - Connecting the Dots to J&J - Updated & Revised

A Study to Assess 18-Methoxycoronaridine

https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine%2C+Inc.&lead_ex=Y&draw=2&rank=1

The current contact for this trial is listed as:

Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer:

https://www.prnewswire.com/news-releases/mindmed-streamlines-leadership-with-further-emphasis-on-integrating-psychedelic-drug-development-with-digital-medicines-and-therapeutics-301219840.html

---

The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were:

Jason Summa - https://www.linkedin.com/in/jasonsumma/Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/

You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document.

https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop

Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence.

They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website:

Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality.



No IND required

Fast-tracked approvals

Generous R&D refunds

Excellent health system Access to patient databases

Data accepted by FDA, EMA, CFDA & PDMA

---

Looks like to me they will fast track in Australia - then partner with J&J if successful.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences